Priscilla Hsue, MD

Professor

Priscilla Hsue MD, is the William Watt Kerr Professor of Medicine at the University of California, San Francisco (UCSF) and works primarily at Zuckerberg San Francisco General. Her training has included a B.S. from Carnegie Mellon University and an MD from the University of California, San Francisco. Dr. Hsue obtained her training in internal medicine and cardiology fellowship also at UCSF. Her research interest is the pathogenesis, clinical manifestations, and treatment of cardiovascular disease and inflammation in HIV-infected individuals.

Dr. Hsue leads a multidisciplinary team and oversees a large portfolio of clinical and translational studies of HIV-related cardiovascular disease. As Co-Director of the Center for Vascular Excellence at UCSF, Dr. Hsue has extensive experience in noninvasive cardiovascular imaging including assessment of carotid artery intima-media thickness, assessment of endothelial function using flow-mediated vasodilation of the brachial artery, and FDG-PET/CT to evaluate arterial inflammation. She has used all of these imaging techniques with the purpose of ascertaining the pathophysiology of HIV-related cardiovascular disease and the role of inflammation in this disease process. Dr. Hsue has published widely in the area of HIV-related cardiovascular disease and inflammation including high-impact publications in Circulation, JACC, JAMA Cardiology, and AIDS. Dr. Hsue established the HIV Cardiology Clinic at San Francisco General Hospital and is one of the few cardiologists internationally with clinical as well as research expertise in this area. She has led numerous studies of anti-inflammatory agents, immunotherapeutic and lipid lowering trials in the setting of HIV, rheumatoid arthritis and atherosclerosis. Dr. Hsue has had continuous NIH funding since 2005 and is PI, co-PI, and co-investigator on numerous NIH-funded grants, was Chair of the Clinical and Integrative Cardiovascular Science Study Section at NHLBI from 2017-2019, and also has served as a member of Office of AIDS Research Advisory Council at the NIH. She was elected into the American Society of Clinical Investigation in 2013 and the Association of University Cardiologists in 2016. Dr. Hsue has mentored numerous medical students, residents, fellows, and junior faculty and is co-PI of a K12 award from NHLBI to train and mentor researchers in HIV-related heart, lung, and blood disease.
Education
Cert, 2006 - Medicine (Advance Training in Clinical Research), University of California, San Francisco
M.D., 1996 - Medicine, University of California, San Francisco
Clinical Fellowship, - School of Medicine, University of California, San Francisco
Residency, - School of Medicine, University of California, San Francisco
Publications
  1. Association of Viral Persistence and Atherosclerosis in Adults With Treated HIV Infection.
  2. An Unusual, Reversible Cause of Acute High-Output Heart Failure Complicated by Refractory Shock.
  3. Impact of polysubstance use on high-sensitivity cardiac troponin I over time in homeless and unstably housed women.
  4. Methamphetamine and cardiac disease among people with HIV infection.
  5. HIV X4 Variants Increase Arachidonate 5-Lipoxygenase in the Pulmonary Microenvironment and are associated with Pulmonary Arterial Hypertension.
  6. Association between statin use, atherosclerosis, and mortality in HIV-infected adults.
  7. HIV and cardiovascular disease.
  8. Plasma tissue factor and immune activation are associated with carotid intima-media thickness progression in treated HIV infection.
  9. The Role of Inflammation in HIV-Associated Atherosclerosis-One Size May Not Fit All.
  10. Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection.
  11. The Golden Compass Program: Overview of the Initial Implementation of a Comprehensive Program for Older Adults Living with HIV.
  12. MicroRNA biomarkers associated with type 1 myocardial infarction in HIV-positive individuals.
  13. Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate.
  14. Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study.
  15. Human Immunodeficiency Virus Infection and Incident Atrial Fibrillation.
  16. Seeing Is Believing: Nuclear Imaging of HIV Persistence.
  17. Mortality following myocardial infarction among HIV-infected persons: the Center for AIDS Research Network Of Integrated Clinical Systems (CNICS).
  18. Periodontal Disease Associates With Arterial Inflammation Via Potentiation of a Hematopoietic-Arterial Axis.
  19. HIV infection and coronary heart disease: mechanisms and management.
  20. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association.
  21. Safety and Impact of Low-Dose Methotrexate on Endothelial Function and Inflammation in Individuals with Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314.
  22. Carnitine Is Associated With Atherosclerotic Risk and Myocardial Infarction in HIV -Infected Adults.
  23. Mechanisms of Cardiovascular Disease in the Setting of HIV Infection.
  24. Unique Circulating MicroRNA Profiles in HIV Infection.
  25. Introduction to Cardiovascular Issues in HIV.
  26. IL-1ß Inhibition Reduces Atherosclerotic Inflammation in HIV Infection.
  27. Brachial Artery Echogenicity and Grayscale Texture Changes in HIV-Infected Individuals Receiving Low-Dose Methotrexate.
  28. Lipid Abnormalities in Persons Living With HIV Infection.
  29. Adjudicated Heart Failure in HIV-Infected and Uninfected Men and Women.
  30. Inflammation, Immunity, and Infection in Atherothrombosis: JACC Review Topic of the Week.
  31. Time to Recognize HIV Infection as a Major Cardiovascular Risk Factor.
  32. Differentiation of Type 1 and Type 2 Myocardial Infarctions among HIV-infected patients requires adjudication due to overlap in risk factors.
  33. Association of Biomarker Clusters With Cardiac Phenotypes and Mortality in Patients With HIV Infection.
  34. Increased Echocardiographic Pulmonary Pressure in HIV-infected and -uninfected Individuals in the Veterans Aging Cohort Study.
  35. Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study.
  36. Comorbidities Among US Patients With Prevalent HIV Infection-A Trend Analysis.
  37. Heart failure in persons living with HIV infection.
  38. Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study.
  39. Healthcare utilization and direct costs of non-infectious comorbidities in HIV-infected patients in the USA.
  40. CHA2DS2-VASc Score, Warfarin Use, and Risk for Thromboembolic Events Among HIV-Infected Persons With Atrial Fibrillation.
  41. Utility of 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines in HIV-Infected Adults With Carotid Atherosclerosis.
  42. PCSK9 Inhibition to Reduce Cardiovascular Risk: Tempering Expectations.
  43. Association of Tenofovir Use With Risk of Incident Heart Failure in HIV-Infected Patients.
  44. Greater Risk of Stroke of Undetermined Etiology in a Contemporary HIV-Infected Cohort Compared with Uninfected Individuals.
  45. Types of Myocardial Infarction Among Human Immunodeficiency Virus-Infected Individuals in the United States.
  46. Association of Arterial and Lymph Node Inflammation With Distinct Inflammatory Pathways in Human Immunodeficiency Virus Infection.
  47. Higher prevalence of detectable troponin I among cocaine-users without known cardiovascular disease.
  48. Role of T-Cell Dysfunction, Inflammation, and Coagulation in Microvascular Disease in HIV.
  49. Plasma IL-6 levels are independently associated with atherosclerosis and mortality in HIV-infected individuals on suppressive antiretroviral therapy.
  50. Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension.
  51. Inflammation and Arterial Injury in Individuals With Human Immunodeficiency Virus Infection.
  52. Immunologic profiles distinguish aviremic HIV-infected adults.
  53. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
  54. PCSK9 Inhibitors for Statin Intolerance?
  55. Inflammation and Fibrosis in HIV: Getting to the Heart of the Matter.
  56. Endothelin-1 Predicts Hemodynamically Assessed Pulmonary Arterial Hypertension in HIV Infection.
  57. Cerebral vasoreactivity is impaired in treated, virally suppressed HIV-infected individuals.
  58. Patterns of Cardiovascular Mortality for HIV-Infected Adults in the United States: 1999 to 2013.
  59. Brief Report: Coordinated Modulation of Circulating miR-21 in HIV, HIV-Associated Pulmonary Arterial Hypertension, and HIV/Hepatitis C Virus Coinfection.
  60. Novel Biomarkers of Cardiac Stress, Cardiovascular Dysfunction, and Outcomes in HIV-Infected Individuals.
  61. Mitral Annular and Coronary Artery Calcification Are Associated with Mortality in HIV-Infected Individuals.
  62. PCSK9 Inhibition to Lower LDL-Cholesterol and Reduce Cardiovascular Risk: Great Expectations.
  63. Correction: A novel minimally-invasive method to sample human endothelial cells for molecular profiling.
  64. Stimulating high impact HIV-related cardiovascular research: recommendations from a multidisciplinary NHLBI Working Group on HIV-related heart, lung, and blood disease.
  65. A novel minimally-invasive method to sample human endothelial cells for molecular profiling.
  66. The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial.
  67. Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials.
  68. Effect of CD4+ cell count and viral suppression on risk of ischemic stroke in HIV infection.
  69. Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis.
  70. The authors reply.
  71. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality.
  72. Arterial disease in patients with human immunodeficiency virus infection: what has imaging taught us?
  73. Lessons learned from the design and implementation of myocardial infarction adjudication tailored for HIV clinical cohorts.
  74. Impact of HIV on CD8+ T cell CD57 expression is distinct from that of CMV and aging.
  75. Increased levels of asymmetric dimethylarginine are associated with pulmonary arterial hypertension in HIV infection.
  76. Effect of left ventricular dysfunction and viral load on risk of sudden cardiac death in patients with human immunodeficiency virus.
  77. Reply to Karch et al.
  78. Physician accuracy in interpreting potential ST-segment elevation myocardial infarction electrocardiograms.
  79. Prehypertension, hypertension, and the risk of acute myocardial infarction in HIV-infected and -uninfected veterans.
  80. Long-term outcomes of patients sent emergently to the catheterization laboratory for possible primary percutaneous coronary intervention.
  81. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial.
  82. Clinical characteristics and reperfusion times among patients with an isolated posterior myocardial infarction.
  83. Emergency medical service utilization and door-to-balloon time for HIV-infected individuals with ST-elevation myocardial infarction.
  84. Endothelial dysfunction in coronary heart disease is more than a systemic process.
  85. Elevated levels of asymmetric dimethylarginine are associated with lower CD4+ count and higher viral load in HIV-infected individuals.
  86. Human immunodeficiency virus-associated pulmonary arterial hypertension.
  87. Atrial fibrillation and atrial flutter in human immunodeficiency virus-infected persons: incidence, risk factors, and association with markers of HIV disease severity.
  88. Comparison of clinical characteristics and outcomes of cardiac arrest survivors having versus not having coronary angiography.
  89. PR Interval and sudden cardiac death in patients with HIV infection.
  90. A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection.
  91. Doppler echocardiography does not accurately estimate pulmonary artery systolic pressure in HIV-infected patients.
  92. Impact of door-to-activation time on door-to-balloon time in primary percutaneous coronary intervention for ST-segment elevation myocardial infarctions: a report from the Activate-SF registry.
  93. Inflammation, immune activation, and CVD risk in individuals with HIV infection.
  94. Prevalence and factors associated with false-positive ST-segment elevation myocardial infarction diagnoses at primary percutaneous coronary intervention–capable centers: a report from the Activate-SF registry.
  95. Immunologic basis of cardiovascular disease in HIV-infected adults.
  96. The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease.
  97. Sudden cardiac death in patients with human immunodeficiency virus infection.
  98. The exposure-dependent effects of aged secondhand smoke on endothelial function.
  99. A role for cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis.
  100. Carotid Intima-Media Thickness Progression in HIV-Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation.
  101. Delaying primary percutaneous coronary intervention for computed tomographic scans in the emergency department.
  102. HIV infection is associated with decreased thrombin generation.
  103. Human Immunodeficiency Virus nef signature sequences are associated with pulmonary hypertension.
  104. Increased CD34+/KDR+ cells are not associated with carotid artery intima-media thickness progression in chronic HIV-positive subjects.
  105. Carotid intima-media thickness among human immunodeficiency virus-infected patients without coronary calcium.
  106. Improvement in revascularization time after creation of a coronary catheterization laboratory at a public hospital.
  107. Hemodynamic and arrhythmogenic effects of cocaine in hypertensive individuals.
  108. Pulmonary hypertension in HIV-infected individuals.
  109. Pathogenesis of HIV-associated pulmonary hypertension: potential role of HIV-1 Nef.
  110. Association of vitamin D insufficiency with carotid intima-media thickness in HIV-infected persons.
  111. Role of biomarkers in predicting CVD risk in the setting of HIV infection?
  112. Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals.
  113. Beta-blockers for chest pain associated with recent cocaine use.
  114. Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease.
  115. Impact of HIV infection on diastolic function and left ventricular mass.
  116. Assessment of structural disease in the coronary microvasculature.
  117. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients.
  118. Cardiovascular manifestations of HIV infection.
  119. Structural and functional manifestations of human atherosclerosis: do they run in parallel?
  120. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis.
  121. Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis.
  122. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association.
  123. Individualized approach to the management of coronary heart disease: identifying the nonresponders before it is too late.
  124. Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy.
  125. Screening and assessment of coronary heart disease in HIV-infected patients.
  126. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary.
  127. Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension.
  128. Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology.
  129. Pulmonary hypertension: an increasingly recognized complication of hereditary hemolytic anemias and HIV infection.
  130. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.
  131. Cardiac arrest in patients who smoke crack cocaine.
  132. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses.
  133. What a cardiologist needs to know about patients with human immunodeficiency virus infection.
  134. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment.
  135. The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection.
  136. Usefulness of serum endothelin levels in predicting death and myocardial infarction but not coronary progression in postmenopausal women with coronary disease (from the Women's Angiographic Vitamin and Estrogen [WAVE] study).
  137. Role of thrombotic and fibrinolytic factors in acute coronary syndromes.
  138. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection.
  139. Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection.
  140. Acute aortic dissection related to crack cocaine.
  141. Low-density-lipoprotein cholesterol goals for patients with coronary disease: treating between the lines.
  142. What is the role of intensive cholesterol lowering in the treatment of acute coronary syndromes?
  143. A 19F-NMR study of the membrane-binding region of D-lactate dehydrogenase of Escherichia coli.
  144. Inactive and temperature-sensitive folding mutants generated by tryptophan substitutions in the membrane-bound d-lactate dehydrogenase of Escherichia coli.